Glenmark Pharmaceuticals Ltd

- There is no explicit mention of any current or future fundraising plans through debt or equity in the provided transcript. - The company discussed increases in net debt primarily due to payments related to a DOJ settlement and the GLS divestment transaction, not new fundraising. - Glenmark is focusing on operational performance improvements and margin expansion rather than raising new funds. - No specific guidance or comments on equity issuance or debt raising were provided during the Q2 FY24 earnings call. - The management appears confident in cash flow improvements in H2 FY24 from business performance and expects to manage existing obligations without new fundraises.

- Consolidated total asset addition in Q2 FY24 was Rs.249.7 crores, including Rs.162.8 crores in tangible assets and Rs.86.9 crores in intangible assets (Page 7). - Ongoing investment in Ichnos: Glenmark invested Rs.1,613 million (~US$19.6 million) in Q2 FY24 and Rs.3,030 million (~US$36.8 million) in H1 FY24, focusing on innovation and strategic growth (Page 7). - No specific new capex guidance mentioned for future quarters, but the company is focusing on operational improvements such as remediation completion at Monroe and market expansions. - Mention of launching new products and expanding presence in key markets like US (respiratory and injectables), Europe, Latin America, and India suggests continued strategic investments in portfolio and geographic diversification (Pages 9, 12, 13). - GLS transaction expected to be recognized in Q3 FY24; post-divestment, capital allocation may shift (Page 7).

- US business: Expected to strengthen in coming years with new product filings (e.g., Fluticasone MDI filing planned between Q4 and Q1) and respiratory product launches; however, near-term outlook uncertain due to market conditions. - Europe and Rest of World (ROW): Strong, broad-based growth expected; Europe targeting 15-20% minimum growth with further margin expansion; ROW (including Asia, Latin America, Middle East, Africa) performing well with key approvals driving growth (e.g., in Brazil, Russia). - India: Anticipated sustained growth of 12-15% over the next three years, driven by RX (respiratory, cardiac, dermatology, diabetes segments), OTC, and institutional business growth. - Glenmark Life Sciences (GLS): being divested, so future consolidation impact to be considered. - Overall: Expectation of strong portfolio with multiple approvals, operating leverage, and margin improvements supporting sales and volume growth across markets.

- Glenmark expects significant improvement in EBITDA margins, targeting close to 19% by FY25, driven by: - 2% margin expansion from lower innovative R&D spend. - Additional margin gains from RYALTRIS and operating leverage in Europe and Latin America. - PAT margins are anticipated to see a notable uplift in FY25 due to lower interest, depreciation, and tax expenses post GLS transaction. - US business is expected to recover with new launches (including respiratory products) and the return of Monroe from next year. - India business is projected to sustain 12-15% growth over the next 2-3 years, led by respiratory, cardiac, dermatology, and OTC segments. - ROW and Europe are robust growth drivers with expected EBITDA margin improvements adding approximately 1-2% each year. - Overall, FY25 is considered a transition year with strong positive earnings trajectory post GLS divestment and remediation cost reductions.

The transcript provided in the document does not explicitly mention the current or expected order book or pending orders for Glenmark Pharmaceuticals. However, some relevant points related to business outlook and product pipeline include: - Glenmark has a healthy portfolio of products being filed, supporting a strong US business outlook in coming years, subject to approvals. - The company plans to file 10 to 12 ANDAs (Abbreviated New Drug Applications) in FY24. - The marketing portfolio as of September 30, 2023, includes 185 generic products authorized in the US and 51 ANDA applications pending. - Several launches in Q3 FY24, including Varenicline tablets via partnership and three injectables, expected to boost sales. - Growth drivers include respiratory, cardiac, dermatology, and OTC segments across India, Europe, and ROW markets. No direct commentary on order book or specific pending orders volume is provided in the transcript.